What’s Next for Innovate Biopharmaceuticals, Inc. (INNT) After Today’s Significant Decline?

April 18, 2018 - By Henry Gaston

The stock of Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) is a huge mover today! The stock decreased 16.81% or $5.05 during the last trading session, reaching $25. About 419,476 shares traded or 24.96% up from the average. Innovate Biopharmaceuticals, Inc. (NASDAQ:INNT) has risen 147.01% since April 18, 2017 and is uptrending. It has outperformed by 135.46% the S&P500.
The move comes after 6 months negative chart setup for the $642.29 million company. It was reported on Apr, 18 by Barchart.com. We have $24.25 PT which if reached, will make NASDAQ:INNT worth $19.27 million less.

Innovate Biopharmaceuticals, Inc., a clinical stage biotechnology company, focuses on developing autoimmune and inflammation therapeutics. The company has market cap of $642.29 million. The Company’s late-stage clinical pipeline focuses on addressing unmet needs in diseases, such as celiac disease, inflammatory bowel disease , and nonalcoholic steatohepatitis (NASH). It currently has negative earnings. The company's lead drug candidate, larazotide acetate (INN-202), has successfully met its primary endpoint in a Phase 2b efficacy clinical trial for celiac disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.